envatinib plus Cisplatin refractory or unsuitable for ICI
Phase 2
Recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-jRCT1041210163
- Lead Sponsor
- Yamashita Tatsuya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; refractory or unsuitable for immune checkpoint inhibitor; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
Exclusion Criteria
refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method